SGLT2 抑制剂与哺乳期之间的比较:对发育期妇女心脏代谢健康的影响
1Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Metabolic syndrome and related disorders
|October 21, 2024
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂和哺乳都促进葡萄糖分泌,并提供心血管保护. 了解它们的共同和独特机制可以改善女性的心脏代谢健康.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 的抑制和哺乳期增加葡萄糖分泌.
- 这两种过程都与降低心血管事件风险有关,但机制尚不清楚.
- 帕鲁斯妇女的心脏代谢健康是重点关注的重点.
研究的目的:
- 为了比较SGLT2抑制期间的非胰岛素介导葡萄糖运输与哺乳期.
- 为了阐明对孕期妇女心脏代谢健康的影响.
- 确定心血管保护的共享和独特机制.
主要方法:
- 关于SGLT2抑制剂的文献综述 (机制,动脉样硬化,心力衰竭).
- 关于哺乳的文献综述 (心血管健康,牛奶成分).
- 检索的文章的参考搜索.
主要成果:
- SGLT2 抑制剂通过脏葡萄糖/运输来防止心力衰竭住院.
- 哺乳刺激乳腺葡萄糖的运输,改善血管疾病.
- 无论是SGLT2抑制剂还是哺乳期都会影响各种葡萄糖转运体.
结论:
- 通过比较SGLT2抑制和哺乳期,可以了解心脏代谢健康状况.
- 了解葡萄糖载体的作用对于心血管保护至关重要.
- 进一步的研究可以促进对所有个体的心脏代谢健康的理解.
相关概念视频
Pathophysiology of Diabetes
874
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
874
Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K


